innovation
Endpoints News to Announce 2025 ‘Endpoints 11’ Biotechs to Watch Live in Boston
Endpoints 11; biotech startups; biopharma; Boston; live event; industry trends; biotech innovation
UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes
UK life sciences; ABPI; VPAG; pharma trade group; investment evaluation; medicines pricing; government review; NHS; innovation; statutory scheme
Amgen to Invest Over $600M in New Innovation Centre at California Headquarters
Amgen; innovation centre; science and innovation hub; Thousand Oaks; California; biotechnology; construction; automation; digital tools; therapeutic development; tax incentives; capital investment
How Science Drives Better Business Decisions in Biopharma (2025 Update)
biopharma; decision science; AI; digital twins; R&D; portfolio strategy; data-driven decisions; innovation; business strategy
Ignoring China’s Biotech Industry Is No Longer an Option: Recent Developments and Implications
China biotech industry; global drug development; clinical trials; innovation ecosystem; pharmaceutical R&D; biotech patents; US-China competition
Inside the FDA’s Listening Tour: Officials Agree US Lags Behind China on Drug Development
FDA; China; drug development; biotechnology; regulation; clinical trials; pharmaceutical industry; biotech innovation
Shrinking Budgets and Rising Targets Pile Pressure on Pharma Marketers: Survey Highlights 2025 Challenges
pharma marketing; shrinking budgets; rising targets; 2025 survey; healthcare marketing trends; budget constraints; innovation; marketing pressure
Biotech Leaders Urge FDA to ‘Modernise’ Regulation to Compete with China
FDA; biotech; regulation; modernization; China; cell and gene therapy; CEO roundtable; competitiveness; innovation
Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey
Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub
Bristol Myers CEO: America’s Biopharma Leadership Not Guaranteed
Bristol Myers Squibb; CEO; Chris Boerner; biopharma; Americas; global competitiveness; dealmaking; innovation; growth portfolio